Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorMonteiro, Wuelton Marcelo-
Autor(es): dc.creatorBrito-Sousa, Jose Diego-
Autor(es): dc.creatorBaía-da-Silva, Djane-
Autor(es): dc.creatorMelo, Gisely Cardoso de-
Autor(es): dc.creatorSiqueira, André Machado-
Autor(es): dc.creatorVal, Fernando-
Autor(es): dc.creatorDaniel-Ribeiro, Cláudio Tadeu-
Autor(es): dc.creatorLacerda, Marcus Vinicius Guimarães-
Data de aceite: dc.date.accessioned2026-02-09T11:58:05Z-
Data de disponibilização: dc.date.available2026-02-09T11:58:05Z-
Data de envio: dc.date.issued2020-05-13-
Data de envio: dc.date.issued2020-05-13-
Data de envio: dc.date.issued2019-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/40879-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1151439-
Descrição: dc.descriptionThe first cases of the new coronavirus (COVID-19) were reported in December, 2019, when a group of patients was admitted to hospitals with an initial diagnosis of pneumonia of unknown etiology1 . Initially, the outbreak of the new SARSCoV-2 coronavirus (coronavirus disease 2019; formerly 2019-nCoV) was centralized in the province of Hubei, Republic of China, and later spread to many other countries2 . SARS-CoV-2 infection appears to cause a wide range of symptoms, encompassing asymptomatic infection, mild infections of the upper respiratory tract, severe viral pneumonia, respiratory failure, multiple organ failure and death3 . Some studies have shown detailed clinical features of some patients with SARSCoV-24 . Of the 44,672 laboratory confirmed patients in China, almost 5% had critical illnesses and almost 50% of the critical patients died, with the overall rate of fatal cases (2.3%) being higher than that observed for seasonal influenza5 . Most deaths involved older adults, many of whom had underlying chronic diseases4,6, while children are less likely to develop severe infections7 . Despite there being no available data so far, anecdotal data from Italy showed a huge number of deaths in the elderly, paving the way for drastic control measures worldwide and compassionate use of drugs in severe cases.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Publicador: dc.publisherSociedade Brasileira de Medicina Tropical-
Direitos: dc.rightsAttribution 4.0 International-
Direitos: dc.rightsAttribution 4.0 International-
Direitos: dc.rightsacesso aberto-
Direitos: dc.rightshttp://creativecommons.org/licenses/by/4.0/-
Direitos: dc.rightshttp://creativecommons.org/licenses/by/4.0/-
???dc.source???: dc.sourceRevista da Sociedade Brasileira de Medicina Tropical-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectCoronavirus-
Palavras-chave: dc.subjectSARS-CoV-2-
Palavras-chave: dc.subjectChloroquine-
Palavras-chave: dc.subjectCloroquina-
Título: dc.titleDriving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.